Medicenna Therapeutics MDNA Stock
Medicenna Therapeutics Price Chart
Medicenna Therapeutics MDNA Financial and Trading Overview
| Medicenna Therapeutics stock price | 0.16 USD |
| Previous Close | 0.61 USD |
| Open | 0.59 USD |
| Bid | 0 USD x 1300 |
| Ask | 0 USD x 1000 |
| Day's Range | 0.56 - 0.62 USD |
| 52 Week Range | 0.4 - 1.88 USD |
| Volume | 75.08K USD |
| Avg. Volume | 79.6K USD |
| Market Cap | 43.59M USD |
| Beta (5Y Monthly) | 0.583453 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.13 USD |
MDNA Valuation Measures
| Enterprise Value | 6.33M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.2962961 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.2997904 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.37 |
Trading Information
Medicenna Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.583453 |
| 52-Week Change | -21.61% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.88 USD |
| 52 Week Low | 0.4 USD |
| 50-Day Moving Average | 0.64 USD |
| 200-Day Moving Average | 0.65 USD |
MDNA Share Statistics
| Avg. Volume (3 month) | 79.6K USD |
| Avg. Daily Volume (10-Days) | 38.81K USD |
| Shares Outstanding | 69.64M |
| Float | 48.74M |
| Short Ratio | 1.63 |
| % Held by Insiders | 23.65% |
| % Held by Institutions | 14.00% |
| Shares Short | 154.14K |
| Short % of Float | 0.33% |
| Short % of Shares Outstanding | 0.22% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | March 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -33.27% |
| Return on Equity (ttm) | -32.98% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -17100000 USD |
| Net Income Avi to Common (ttm) | -9398000 USD |
| Diluted EPS (ttm) | -0.13 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 36.15M USD |
| Total Cash Per Share (mrq) | 0.52 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 7.701 |
| Book Value Per Share (mrq) | 0.477 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -13263000 USD |
| Levered Free Cash Flow (ttm) | -5984375 USD |
Profile of Medicenna Therapeutics
| Country | United States |
| State | ON |
| City | Toronto |
| Address | 2 Bloor Street West |
| ZIP | M4W 3E2 |
| Phone | N/A |
| Website | https://www.medicenna.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 18 |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Q&A For Medicenna Therapeutics Stock
What is a current MDNA stock price?
Medicenna Therapeutics MDNA stock price today per share is 0.16 USD.
How to purchase Medicenna Therapeutics stock?
You can buy MDNA shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Medicenna Therapeutics?
The stock symbol or ticker of Medicenna Therapeutics is MDNA.
Which industry does the Medicenna Therapeutics company belong to?
The Medicenna Therapeutics industry is Biotechnology.
How many shares does Medicenna Therapeutics have in circulation?
The max supply of Medicenna Therapeutics shares is 0.
What is Medicenna Therapeutics Price to Earnings Ratio (PE Ratio)?
Medicenna Therapeutics PE Ratio is 0.00000000 now.
What was Medicenna Therapeutics earnings per share over the trailing 12 months (TTM)?
Medicenna Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Medicenna Therapeutics company belong to?
The Medicenna Therapeutics sector is Healthcare.
Medicenna Therapeutics MDNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 18737.21 USD — |
-1
|
7.88B USD — | 18599.69 USD — | 18841.52 USD — | — - | 7.88B USD — |
| Nasdaq Health Care IXHC | 932.02 USD — |
-0.03
|
— — | 920.46 USD — | 933.54 USD — | — - | — — |
- {{ link.label }} {{link}}